Lutetium (lu177) lilotomab satetraxetan by Thor Medical for B-Cell Chronic Lymphocytic Leukemia: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Lutetium (lu177) lilotomab satetraxetan overview

Betalutin (177Lu-HH1) is under development for the treatment of non-Hodgkin B-cell lymphoma of subtypes follicular grade I-IIIA, marginal zone, small lymphocytic, lymphoplasmacytic, mantle cell lymphoma and other non-hodkin’s lymphomas in combination with CD20. It is administered as an intravenous and parenteral route. The drug candidate is a monoclonal antibody (HH1) conjugated with a radionuclide Lutetium-177 (177Lu). It is a radioimmunotherapeutic developed using nanovector targeting technology. Betalutin targets CD37 antigen.

It was under development for the treatment of diffuse large B-cell lymphoma.

Thor Medical overview

Thor Medical, formerly Nordic Nanovector, is a developer and commercializer of antibody radionuclide conjugates for the treatment of hematological cancers. The company’s lead product candidate includes Betalutin, an antibody radionuclide conjugate developed for the treatment of non-Hodgkin Lymphoma, a life-threatening blood cancer. Its Betalutin consists of the tumor-specific antibody HH1, which targets CD37 antigen on the surface of NHL cells. Thor Medical develops products for the treatment of multiple cancer indications by utilizing innovative therapy programs and patented technologies. The company evaluates chimeric anti-CD37 antibodies with different payloads for the treatment of both types of leukemia. It also provides pipeline products Humalutin, Zr-NNV003, Alpha37, and CD37-targeting. It operates in Norway, Switzerland and the UK. Thor Medical is headquartered in Oslo, Norway.

For a complete picture of Lutetium (lu177) lilotomab satetraxetan’s drug-specific PTSR and LoA scores, buy the report here.

Sign up for our daily news round-up!

Give your business an edge with our leading industry insights.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.